<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35337852</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0038</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>827</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Gene</Title>
          <ISOAbbreviation>Gene</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nanog, as a key cancer stem cell marker in tumor progression.</ArticleTitle>
        <Pagination>
          <StartPage>146448</StartPage>
          <MedlinePgn>146448</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gene.2022.146448</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0378-1119(22)00267-0</ELocationID>
        <Abstract>
          <AbstractText>Cancer stem cells (CSCs) are a small population of malignant cells that induce tumor onset and development. CSCs share similar features with normal stem cells in the case of self-renewal and differentiation. They also contribute to chemoresistance and metastasis of cancer cells, leading to therapeutic failure. To identify CSCs, multiple cell surface markers have been characterized, including Nanog, which is found at high levels in different cancers. Recent studies have revealed that Nanog upregulation has a substantial association with the advanced stages and poor prognosis of malignancies, playing a pivotal role through tumorigenesis of multiple human cancers, including leukemia, liver, colorectal, prostate, ovarian, lung, head and neck, brain, pancreatic, gastric and breast cancers. Nanog through different signaling pathways, like JAK/STAT and Wnt/β-catenin pathways, induces stemness, self-renewal, metastasis, invasiveness, and chemoresistance of cancer cells. Some of these signaling pathways are common in various types of cancers, but some have been found in one or two cancers. Therefore, this review aimed to focus on the function of Nanog in multiple cancers based on recent studies surveying the suitable approaches to target Nanog and inhibit CSCs residing in tumors to gain favorable results from cancer treatments.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Vasefifar</LastName>
            <ForeName>Parisa</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Motafakkerazad</LastName>
            <ForeName>Rouhollah</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Plant Biology, Faculty of Natural Science, University of Tabriz, Iran. Electronic address: rmotafakker@tabrizu.ac.ir.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maleki</LastName>
            <ForeName>Leili Aghebati</ForeName>
            <Initials>LA</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Najafi</LastName>
            <ForeName>Souzan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ghrobaninezhad</LastName>
            <ForeName>Farid</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Najafzadeh</LastName>
            <ForeName>Basira</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alemohammad</LastName>
            <ForeName>Hajar</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amini</LastName>
            <ForeName>Mohammad</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baghbanzadeh</LastName>
            <ForeName>Amir</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baradaran</LastName>
            <ForeName>Behzad</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Pharmaceutical Analysis Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: baradaranb@tbzmed.ac.ir.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Gene</MedlineTA>
        <NlmUniqueID>7706761</NlmUniqueID>
        <ISSNLinking>0378-1119</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C486780">NANOG protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071317">Nanog Homeobox Protein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071317" MajorTopicYN="Y">Nanog Homeobox Protein</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="Y">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060449" MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cancer stem cells</Keyword>
        <Keyword MajorTopicYN="N">Nanog</Keyword>
        <Keyword MajorTopicYN="N">Tumor Marker</Keyword>
        <Keyword MajorTopicYN="N">Tumor progression</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>5</Hour>
          <Minute>28</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35337852</ArticleId>
        <ArticleId IdType="doi">10.1016/j.gene.2022.146448</ArticleId>
        <ArticleId IdType="pii">S0378-1119(22)00267-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35337852</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0038</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>827</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Gene</Title>
          <ISOAbbreviation>Gene</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nanog, as a key cancer stem cell marker in tumor progression.</ArticleTitle>
        <Pagination>
          <StartPage>146448</StartPage>
          <MedlinePgn>146448</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gene.2022.146448</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0378-1119(22)00267-0</ELocationID>
        <Abstract>
          <AbstractText>Cancer stem cells (CSCs) are a small population of malignant cells that induce tumor onset and development. CSCs share similar features with normal stem cells in the case of self-renewal and differentiation. They also contribute to chemoresistance and metastasis of cancer cells, leading to therapeutic failure. To identify CSCs, multiple cell surface markers have been characterized, including Nanog, which is found at high levels in different cancers. Recent studies have revealed that Nanog upregulation has a substantial association with the advanced stages and poor prognosis of malignancies, playing a pivotal role through tumorigenesis of multiple human cancers, including leukemia, liver, colorectal, prostate, ovarian, lung, head and neck, brain, pancreatic, gastric and breast cancers. Nanog through different signaling pathways, like JAK/STAT and Wnt/β-catenin pathways, induces stemness, self-renewal, metastasis, invasiveness, and chemoresistance of cancer cells. Some of these signaling pathways are common in various types of cancers, but some have been found in one or two cancers. Therefore, this review aimed to focus on the function of Nanog in multiple cancers based on recent studies surveying the suitable approaches to target Nanog and inhibit CSCs residing in tumors to gain favorable results from cancer treatments.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Vasefifar</LastName>
            <ForeName>Parisa</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Motafakkerazad</LastName>
            <ForeName>Rouhollah</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Plant Biology, Faculty of Natural Science, University of Tabriz, Iran. Electronic address: rmotafakker@tabrizu.ac.ir.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maleki</LastName>
            <ForeName>Leili Aghebati</ForeName>
            <Initials>LA</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Najafi</LastName>
            <ForeName>Souzan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ghrobaninezhad</LastName>
            <ForeName>Farid</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Najafzadeh</LastName>
            <ForeName>Basira</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alemohammad</LastName>
            <ForeName>Hajar</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amini</LastName>
            <ForeName>Mohammad</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baghbanzadeh</LastName>
            <ForeName>Amir</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baradaran</LastName>
            <ForeName>Behzad</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Pharmaceutical Analysis Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: baradaranb@tbzmed.ac.ir.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Gene</MedlineTA>
        <NlmUniqueID>7706761</NlmUniqueID>
        <ISSNLinking>0378-1119</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C486780">NANOG protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071317">Nanog Homeobox Protein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071317" MajorTopicYN="Y">Nanog Homeobox Protein</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="Y">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060449" MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cancer stem cells</Keyword>
        <Keyword MajorTopicYN="N">Nanog</Keyword>
        <Keyword MajorTopicYN="N">Tumor Marker</Keyword>
        <Keyword MajorTopicYN="N">Tumor progression</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>5</Hour>
          <Minute>28</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35337852</ArticleId>
        <ArticleId IdType="doi">10.1016/j.gene.2022.146448</ArticleId>
        <ArticleId IdType="pii">S0378-1119(22)00267-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
